Hassan’s practice focuses on advising a broad range of clients across the health care industry—including health care systems, pharmacies, and private equity firms investing in health care companies—in complex industry transactions and compliance and regulatory matters.
Hassan leverages his prior experience as a “deal team” attorney representing private equity firms through various mergers and acquisitions, restructurings, and growth equity transactions to provide reasoned and pragmatic solutions to a wide range of client needs.
Prior to joining Mintz, Hassan was an associate with a large, international law firm in New York City, and then later, with a boutique law firm in Los Angeles. He also served as an intern at the State Department’s White House Liaison Office during the Obama administration.
Hassan received his J.D. from Duke Law School, where he was an editor of the Duke Journal of Constitutional Law and Public Policy. He received his B.S.Ed and MPH from Baylor University, with a concentration in health education.
Education
- Duke University (JD)
- Baylor University (MPH)
- Baylor University (BSED)
Involvement
- Member, American Bar Association
- Member, American Health Law Association
- Member, Health Care Compliance Association
Languages
- Urdu
Recent Insights
Viewpoints
PBMs Continue to Draw Federal Scrutiny: PBM Transparency Act of 2022
June 30, 2022 |Blog
News & Press
In a recent installment of Law360 Pulse’s “Ask a Mentor” column, Managing Member of Mintz’s Washington, D.C. Office and Chair of the firm’s Health Law, Communications, Antitrust & ML Strategies Division Susan Berson, who regularly mentors firm attorneys, and Associate Hassan Shaikh, who transitioned from a private equity mergers and acquisitions practice to a health care regulatory role, offered retooling tips to associates.
Brochures
Viewpoints
PBMs Continue to Draw Federal Scrutiny: PBM Transparency Act of 2022
June 30, 2022 | Blog | By Bridgette Keller, Hassan Shaikh, Sergey Smirnov, Jewel Duberry-Douglas
As we noted in our last PBM Regulatory Roundup, there has been a wave of state regulation focused on PBM practices in the wake of Rutledge and Webhi. However, PBMs are also facing federal reform efforts. The Pharmacy Benefit Manager (PBM) Transparency Act of 2022 (the Act) was recently proposed in the U.S. Senate and intends to incentivize “fair and transparent” PBM practices, prohibit spread pricing and claw backs of payments to pharmacies, and empower the Federal Trade Commission (“FTC”) and state attorneys general in enforcement actions to stop “unfair and deceptive” PBM business practices.
At the same time, government watchdogs are also taking action: on June 7, 2022, the FTC announced that it would launch an inquiry into vertically integrated PBMs, and the Office of the Inspector General (OIG) for the Department of Health and Human Services expects to release a report in 2022 following completion of its analysis of Medicaid Managed Care Organization (MCO) PBM pricing.
Read more
At the same time, government watchdogs are also taking action: on June 7, 2022, the FTC announced that it would launch an inquiry into vertically integrated PBMs, and the Office of the Inspector General (OIG) for the Department of Health and Human Services expects to release a report in 2022 following completion of its analysis of Medicaid Managed Care Organization (MCO) PBM pricing.
Health Law Diagnosed — Key Takeaways from the 6th Annual Pharmacy & Pharmaceutical Industry Summit
April 7, 2022 | Podcast | By Stephnie John, Bridgette Keller, Hassan Shaikh
The latest episode of Mintz’s Health Law Diagnosed podcast covers key takeaways from our 6th Annual Pharmacy & Pharmaceutical Industry Summit.
Read more
PBM Regulatory Roundup (Spring 2022): The 8th Circuit Rules and More States Issue Regulations
March 29, 2022 | Blog | By Hassan Shaikh, Bridgette Keller
As states move forward with their 2022 legislative sessions in earnest, we have been examining whether the Wehbi decision has had any initial effects on PBM-focused legislation. This roundup provides a brief recap of the significance of Wehbi, summarizes the Eighth Circuit’s opinion and holding, and highlights some state measures that have been proposed or passed during the flurry of PBM-focused legislation we have already seen in 2022.
Read more
CMS Proposes Changes to Part D Regulations: Pharmacy Price Concessions
January 24, 2022 | Blog | By Hassan Shaikh
The next post in our series analyzing the recently proposed Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs rule (Proposed Rule), focuses on a regulation impacting Part D sponsors and their reporting of pharmacy price concessions. According to CMS, the proposed change—which would require the “negotiated price” of a covered Plan D drug to be the lowest possible payment made to a pharmacy by a Plan D sponsor—is expected to (i) reduce out-of-pocket costs for plan beneficiaries at the pharmacy counter, (ii) create greater drug price transparency, (iii) stabilize the operating environment for pharmacies and (iv) improve market competition.
Read more
Health Law Diagnosed — Mintz’s 2022 Health Law New Year’s Resolutions
January 12, 2022 | Podcast | By Bridgette Keller
In this episode of the Health Law Diagnosed podcast, members of the Mintz Health Law team discuss their health law–focused 2022 New Year’s resolutions and how they’re helping clients and colleagues navigate the continued challenges and opportunities of the current era.
Read more
PBM Regulatory Landscape Roundup (Summer 2021): A Flurry of Regulations, Rutledge, and a Crucial 8th Circuit Decision
September 28, 2021 | Blog | By Hassan Shaikh, Bridgette Keller
As our colleagues predicted, the Supreme Court’s decision in Rutledge v. Pharmaceutical Care Management Association (PCMA) encouraged state efforts to expand regulation of pharmacy benefit managers (PBM) and related practices. And as expected, this year has already seen an aggressive round of state legislation that aims to expand regulation in this area.
Read more
Fourth Time’s the Charm? How COVID-19 May Spur Congress to Pass Legislation Expanding Coverage for Pharmacist Services
May 12, 2021 | Blog | By Hassan Shaikh, Theresa Carnegie
On April 22, 2021, Reps. G.K. Butterfield (D-NC) and David McKinley (R-WV) introduced H.R. 2759, or the Pharmacy and Medically Underserved Areas Enhancement Act. Its introduction marks a fourth bipartisan effort in the House to enact the legislation, which would allow Medicare to directly reimburse pharmacists for delivering certain health care services to Medicare beneficiaries living in areas with limited access to primary medical care. Hindsight suggests that when introduced in the past, the Act may not have been ripe for consideration. But now, in the wake of the COVID-19 pandemic and on the heels of successful initiatives like the West Virginia vaccine rollout, Congress may not wish to table discussion of the legislation any longer.
Read more
News & Press
Ask A Mentor: How Can I Successfully Switch Practices?
November 9, 2021
In a recent installment of Law360 Pulse’s “Ask a Mentor” column, Managing Member of Mintz’s Washington, D.C. Office and Chair of the firm’s Health Law, Communications, Antitrust & ML Strategies Division Susan Berson, who regularly mentors firm attorneys, and Associate Hassan Shaikh, who transitioned from a private equity mergers and acquisitions practice to a health care regulatory role, offered retooling tips to associates.